文献速递泌尿男性生殖肿瘤

恩扎卢胺治疗mCRPC中18F-NaF PET/CT与循环肿瘤细胞的空间-时间变化探索

Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide.
PubMed 文献 · J Clin Oncol · 2020-09-08

本研究纳入23例进展性mCRPC男性,接受恩扎卢胺160 mg每日治疗,用18F-NaF PET/CT定量总骨成像在基线、第13周及进展时评估病灶水平反应。主要终点为PET3时至少一个响应骨病灶的比例,结果显示22/22可评估者均至少有一个响应病灶,且SUVhetero变化是PSA进展的最强预测因子。

要点

  • 恩扎卢胺治疗中整体功能负荷改善,进展时总负荷增加。
  • 所有可评估患者进展时仍至少有一个响应骨病灶。
  • SUVhetero变化是PSA进展的最强预测因子。

核心结论

  • 进展时响应病灶比例低,提示大量病灶在进展后仍可能从恩扎卢胺获益。
  • 选择性靶向非响应病灶可能是延长获益的合理策略。

研究设计与样本

  • 前瞻性研究纳入23例进展性mCRPC男性,至少两个骨扫描病灶,接受恩扎卢胺160 mg每日治疗。
  • 18F-NaF PET/CT在基线(PET1)、第13周(PET2)及进展或2年无进展时(PET3)进行。
  • 采用定量总骨成像(QTBI)确定病灶水平反应。

主要发现

  • 治疗持续时间范围为1.4至34.1个月。
  • 整体SUV指标在恩扎卢胺治疗中(PET2)下降,进展时(PET3)上升。
  • SUVhetero变化(PET1至PET3)是PSA进展的最强预测因子(HR 3.88,95% CI 1.24-12.1)。
  • 所有22/22可评估男性在PET3时至少有一个响应骨病灶。

临床怎么用

  • 18F-NaF PET/CT QTBI可评估mCRPC骨病灶异质性反应,识别进展后仍获益患者。
  • 进展时选择性靶向非响应病灶可能延长恩扎卢胺获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intrapatient treatment response heterogeneity is under-recognized. Quantitative total bone imaging (QTBI) using 18F-NaF positron emission tomography/computed tomography (PET/CT) scans is a tool that allows characterization of interlesional treatment response heterogeneity in bone. Understanding spatial-temporal response is important to identify individuals who may benefit from treatment beyond progression. PATIENTS AND METHODS: Men with progressive metastatic castration-resistant prostate cancer (mCRPC) with at least two lesions on bone scintigraphy were enrolled and treated with enzalutamide 160 mg daily (ClinicalTrials.gov identifier: NCT02384382). 18F-NaF PET/CT scans were obtained at baseline (PET1), week 13 (PET2), and at the time of prostate-specific antigen (PSA) progression, standard radiographic or clinical progression, or at 2 years without progression (PET3). QTBI was used to determine lesion-level response. The primary end point was the proportion of men with at least one responding bone lesion on PET3 using QTBI. RESULTS: Twenty-three men were enrolled. Duration on treatment ranged from 1.4 to 34.1 months. In general, global standardized uptake value (SUV) metrics decreased while on enzalutamide (PET2) and increased at the time of progression (PET3). The most robust predictor of PSA progression was change in SUVhetero (PET1 to PET3; hazard ratio, 3.88; 95% CI, 1.24 to 12.1). Although overall functional disease burden improved during enzalutamide treatment, an increase in total burden (SUVtotal) was seen at the time of progression, as measured by 18F-NaF PET/CT. All (22/22) evaluable men had at least one responding bone lesion at PET3 using QTBI. CONCLUSION: We found that the proportion of progressing lesions was low, indicating that a substantial number of lesions appear to continue to benefit from enzalutamide beyond progression. Selective targeting of nonresponding lesions may be a reasonable approach to extend benefit.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kyriakopoulos CE, Heath EI, Ferrari A, et al. Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. J Clin Oncol. 2020. PMID: 32897830. doi:10.1200/JCO.20.00348

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。